Back To Search Results

Androgen Insensitivity Syndrome

Editor: Stella Ilyayeva Updated: 2/28/2023 10:52:52 AM


Androgen insensitivity syndrome (AIS) is a common etiology of sexual developmental disorders resulting in varying phenotypes. These disorders of androgen action present as 46 XY disorders or differences of sex development (DSD). The phenotypic spectrum of AIS depends on the residual androgen receptor activity and encompasses individuals with a completely female phenotype to male phenotype with infertility/undervirilization.[1] Androgen resistance results in complete androgen insensitivity syndrome (CAIS), characterizing XY sex reversal with normal female phenotype, whereas phenotype diversity is variable with residual androgen receptor activity, which leads to partial androgen insensitivity syndrome (PAIS). PAIS presents a substantial challenge to the clinician in determining the gender identity at the time of the birth of the child. Therefore, it is crucial for the clinician to have an understanding of the physiology of the androgen receptors mechanism to diagnose the condition as CAIS or PAIS accurately and plan the treatment course from birth to adulthood.


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


Androgen insensitivity syndrome arises from loss-of-function mutations in the coding sequence of the androgen receptors (AR). This X-linked genetic mutation of the androgen receptor gene results in the dysfunction of androgen receptors and hormone resistance. These mutations lead to a loss in virilization or infertility in 46XY males in individuals with functional testes and adequate testosterone production. CAIS and PAIS encompass variability in phenotypic expression; however, both these conditions have similar genetic, endocrine, and pathophysiologic mechanisms.[2]


The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) classifies androgen insensitivity syndrome and its subtypes as “rare disease,” which signifies that it affects less than 20,000 people in the US population. The prevalence of 46XY phenotypic females is low, which limits the data about the age and clinical presentation at diagnosis for AIS. As per a nationwide study in Denmark, all known females with 46XY karyotype females since 1960 were analyzed via medical record evaluation and found to have a prevalence of 6.4 per 100000 live-born females. The prevalence of AIS was found to be 4.1 per 100000 live-born females.[3] The prevalence of CAIS proven via molecular diagnosis is estimated to range from 1 in 20400 to 1 in 99100 genetic males.[4]


Androgen insensitivity syndrome is the result of profound resistance of the androgen receptor towards the action of androgen. Various studies done in women established the androgen receptor (AR) dysfunction with no detectable androgen receptor binding, leading to resistance to the virilization effect of the exogenous androgen. The androgen receptor nuclear receptor contains a hormone-binding domain and an N-terminal region used for transactivation, and most mutations cause androgen receptor dysfunction to localize specifically in the hormone-binding domain.[5]

History and Physical

Androgen insensitivity syndrome may subclassify in the form of the following clinical entities: complete androgen insensitivity syndrome (CAIS), partial androgen insensitivity syndrome (PAIS), and mild androgen insensitivity syndrome (MAIS).[6]


There are various forms of presentations of CAIS in different age groups, varying from infants to adolescent females. CAIS will present very commonly as primary amenorrhea in adolescent females or incidental finding of testes in females undergoing inguinal hernia repair. Physical examination reveals a female phenotype at birth, which will be a mismatch from the results of prenatal fetal sexing (Y chromosome on DNA analysis). The vagina is blind-ending with no uterus. Gonads are present in the lower abdomen or inguinal canal. At puberty, with the normal growth spurt, there is breast development secondary to the conversion of androgens to estrogens and a taller female phenotype secondary to the effect of the Y chromosome.


PAIS results in a varied phenotype from the residual androgen receptor function. Symptoms vary from severe under-masculinization with female genitalia to male genitalia. The physical examination will be pertinent for hypospadias, bifid scrotum, and micropenis.


This usually presents as a normal male phenotype with isolated micropenis. In adulthood, it may be associated with gynecomastia and infertility.


The diagnosis of CAIS and PAIS includes assessing clinical and biochemical features, 46 XY karyotype, and exclusion of defects in testosterone synthesis. Furthermore, confirmation is possible with genetic testing.

Exclusion of Defects in Testosterone Synthesis

Studies suggest measuring levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in the first year of life. The expected postnatal surge in gonadotropins and testosterone is usually present in PAIS but may not occur in CAIS as the gonadotropins surge is androgen-dependent.[7] However, there is normal Sertoli cell function exhibited by the normal or even elevated levels of Inhibin B or anti-müllerian hormone (AMH).[8] In children, assessment of testosterone synthesis requires a human chorionic gonadotropin (hCG) stimulation test with measurement of serum androstenedione, testosterone, and dihydrotestosterone (DHT) 72 hours afterward. In adults, testing can be via basal hormone measurements.

17-beta-hydroxysteroid dehydrogenase deficiency: CAIS and PAIS individuals have normal testosterone responses after the hCG stimulation test.[9] Low serum testosterone synthesis implies impaired testosterone synthesis secondary to 17-beta-hydroxysteroid dehydrogenase deficiency.

5-alpha-reductase deficiency: Differentiation of CAIS and PAIS from 5-alpha-reductase is done by analyzing the ratio of testosterone to DHT in serum. In patients with steroid 5-alpha-reductase 2 deficiency, the production of DHT decreases, and the plasma ratio of testosterone to DHT increases. In most girls/boys with PAIS, the production of DHT and the ratio of testosterone to DHT is normal. Women with CAIS may have secondary 5-alpha-reductase deficiency due to a decreased mass of the urogenital tract tissues, which normally produce DHT.

Importance of Genetic Testing in the Evaluation of AIS

In addition to clinical features, biochemical testing may not be adequate to establish the diagnosis of CAIS or PAIS. Therefore, molecular genetic studies become imperative to diagnose CAIS or PAIS. CAIS confirmation is possible with genetic testing locations where the typical loss-of-function mutations in the coding sequence of the androgen receptor exist. The AR gene is on chromosome Xq11-12. It encodes a protein that composes the typical three major functional domains of the nuclear receptor superfamily. In patients with AIS, research has described large structural alterations along with over 1000 mutations. Multiplex ligation-dependent probe amplification (MLPA) analysis is a study available to detect deletions or duplications of exons or the entire gene.[10] The mutational analysis may confirm the diagnosis of androgen insensitivity syndrome. However, PAIS still poses a substantial amount of challenge for clinicians to predict a genotype-phenotype correlation and further clinical prognosis.

Treatment / Management

Management of androgen insensitivity syndrome involves a holistic approach toward the psychological, physiological, and social well-being of the individual suffering from this disorder. It is imperative to address the challenges foreseen to the family of the infant who is born with AIS to optimize well being of the infant into adulthood. Given the irreversibility of the development during embryogenesis in AIS, management involves counseling families, appropriate gender assignment, and improving functional status with time and timing of gonadectomy to prevent tumorigenesis. 

Complete Androgen Insensitivity Syndrome (CAIS)

CAIS presents as an incidental finding of gonad at the time of inguinal hernia repair or as primary amenorrhea in females. It is advisable to obtain a biopsy of the gonad at the time of hernia repair and replace it back either subcutaneously or within the abdomen while further discussion with the parents about the diagnosis and plans for future management are pending.[11]

Parents can choose early gonadectomy to prevent tumorigenesis when complete androgen insensitivity presents in infancy, and the child is unaware of the issues around the diagnosis of CAIS. In this scenario, puberty induction can be done later via estrogen replacement. Also, since women with CAIS do not have a uterus, the risk of estrogen-induced cancer is absent. Alternatively, gonadectomy can be delayed until early adulthood, in which scenario there is a low risk of gonadal tumor in childhood.[12] However, there is no necessity for puberty induction via external estrogen replacement. Puberty occurs spontaneously, manifesting as standard breast development and an appropriately timed growth spurt; however, it is not followed by menarche.

Surgical management in CAIS includes vaginal dilation and rarely vaginoplasty for normal sexual functioning and well-being. 

Partial Androgen Insensitivity Syndrome (PAIS)

Unlike CAIS, infants with PAIS are usually born with ambiguous genitalia, which presents the necessity for an accurate diagnosis primarily and a decision on sex assignment after a holistic discussion with family and caregivers. After that, the clinician can address early management issues. 

In infants assigned as males, medical management includes androgen supplementation at the time of puberty. Surgical management includes the correction of hypospadias and undescended testes. These procedures are preferable during the 2nd to 3rd year of life. At the time of puberty, gynecomastia may develop, which should be corrected with reduction mammoplasty to prevent tumorigenesis. However, the incidence of breast cancer in men with PAIS is low.[13](B3)

Management of PAIS in infants assigned as females includes estrogen supplementation at the time of puberty, along with genitoplasty with gonadectomy before the onset of puberty.

Differential Diagnosis

The differential diagnosis of CAIS includes disorders of androgen biosynthesis or Leydig cell dysfunction, Mullerian agenesis, mixed gonadal dysgenesis, etc. Defects in testosterone synthesis can be the result of a defect in any of the enzymes in the pathway of testosterone synthesis or dysfunction of the LH receptor. Women with Leydig cell dysfunction are 46, XY genotype, who lack pubertal development and have hypogonadotropic hypogonadism. Mullerian agenesis (Mayer-Rokitansky-Kuster-Hauser syndrome) is included in the differential in a female who presents with primary amenorrhea, absent uterus, and blind vaginal pouch.[14] The difference is that women with Mullerian agenesis, a 46 XX karyotype, have normal ovarian function, serum androgen, and estrogen concentrations and, therefore, present with normal axillary and pubic hair.

The differential diagnosis of PAIS may be extensive, given the variable genotypic and phenotypic presentations. The most common differentials to consider are the disorders of androgen synthesis, as mentioned above, along with disorders of gonadal dysgenesis. 46, XY women with a uterus present with gonadal dysgenesis. Mixed gonadal dysgenesis (also termed chromosomal disorder of sex development [DSD]), as the name suggests, is associated with a mosaic 45, X/46, XY karyotype and the presence of a single descended gonad. It presents with a dysgenetic testis on one side and a streak gonad on the other. Partial gonadal dysgenesis has a 46 XY karyotype and is characterized by the presence of müllerian structures but decreased testosterone and anti-müllerian hormone (AMH) and or inhibin B production. The phenotypic variability of partial gonadal dysgenesis is from genital ambiguity to an under-virilized male.

Surgical Oncology

Androgen insensitivity syndrome and individuals with cryptorchid testes have an increased risk of tumorigenesis. Cryptorchidism in partial androgen insensitivity syndrome (PAIS) should be corrected surgically soon after diagnosis to maintain testicular function and minimize the risk of malignancy. These tumors may be germ cell tumors and gonadoblastomas. They tend to occur in approximately 1.5 to 2 percent of undescended testes and may become malignant.[15] Carcinoma in situ or intra-tubular germ cell neoplasia unclassified the premalignant precursor from which tumors associated with AIS arise.[16] Carcinoma in situ arises from gonocytes or primordial germ cells and is thought to be the result of a developmental arrest of fetal germ cells. Carcinoma in situ will lead to the development of a gonadoblastoma in more than 50% of cases. The risk of germ-cell tumors is higher in PAIS than in CAIS, and studies suggest an incidence of 15% and even higher if the testes are not scrotal in position.[17] Women with complete androgen insensitivity syndrome are advised strongly to have a gonadectomy because of the tumor risk, which might increase substantially in later adulthood.[18] Monitoring for carcinoma is based primarily on imaging studies.


Studies have suggested an increased tumor risk of greater than 30% in late adulthood if a gonadectomy is not done.[19] Boys with genetically confirmed PAIS are likely to have a poorer clinical outcome than those with XY DSD, with normal T synthesis, and without an identifiable AR mutation.[20]


Untreated or inadequately managed AIS may result in severe psychological distress in patients as they go through puberty into adulthood and their families at the same time. Psychological distress is more frequent in adults with partial androgen insensitivity syndrome than in those with complete androgen insensitivity syndrome, irrespective of whether they were raised as male or female. Bouvattier C et al. conducted a study of men with partial androgen insensitivity syndrome, and they noted that in men with PAIS, all aspects of sexual activity were substantially impaired.[21]

Postoperative and Rehabilitation Care

Children diagnosed with AIS will need gonadectomy before puberty to avoid the masculinization of females affected by this condition and to prevent the development of gonadal tumors. Vaginal surgery is rarely indicated for the creation of a functional vagina. Vaginal dilators are an effective first-line treatment to increase the length of an existing short vagina.[19] The interprofessional team plays a crucial role in looking after patients with AIS throughout their journey from the time of being diagnosed with this condition and thereafter. A sensitive and open approach is mandatory during the discussion of the postoperative care plan, taking into consideration the patient's views as well as the family's expectations. Psychosocial support is an integral aspect of the holistic approach to the management of patients with AIS and their families.

Deterrence and Patient Education

Education of the families with newborns with androgen insensitivity syndrome is vital for optimizing the plan of care for the newborn into adulthood, which is achievable by undertaking an interprofessional team approach with the help of the clinician, geneticist, along with support groups to tailor the needs of the individual suffering from this disorder and their families. The nurse has a paramount role in educating patients with AIS and their families and making sure they have access to community support groups and to educational materials.

Enhancing Healthcare Team Outcomes

The diagnosis of AIS carries a tremendous negative impact on the patients and their families. It is imperative to follow an interprofessional approach when treating patients with androgen insensitivity syndrome. It requires management by an interprofessional team of healthcare professionals, including an endocrinologist (pediatric or adult), urologist, gynecologist, primary care provider, clinical psychologist, neonatologist, clinical genetics, medical ethics, physician assistants, specialty-trained nurses, and social services. This interprofessional approach assists in appropriate and sensitive management of the condition and prepares the child and the family to overcome the challenges with additional support from patient advocacy groups. Pasterskietal et al. conducted a study to assess the clinical management of disorders of sex development (DSD) with the help of an online questionnaire and audit of DSD literature sent to pediatric endocrinologists from 60 medical centers representing 23 European countries. They studied the interprofessional team composition, psychological support services, and also the incidence of feminizing clitoroplasty. The study noted that 57% of centers regularly included the interprofessional approach utilizing the services of recommended pediatric subspecialists: pediatric endocrinologist, pediatric surgeon/urologist, plastic surgeon, pediatric psychiatrist/psychologist, gynecologist, clinical geneticist, histopathologist, and neonatologist. [Level 5][22]

The interprofessional approach is also beneficial in the education of healthcare professionals to interpret diagnostic tests accurately and avoid incorrect diagnoses and treatment of individuals from infancy to adulthood.[23] There is still a vast scope to improve the diagnosis and management of all causes of XY disorders of sex development (including complete and particularly partial androgen insensitivity syndromes), requiring multicenter collaboration at national and international levels.

In order to care for this disease, an interprofessional approach will provide the best results. The pharmacist should assist the clinician in appropriate dosing and monitoring for untoward side effects of hormonal therapy. The specialty-trained nurses caring for patients with this disease must be familiar with the signs and symptoms as well as complications of their treatment. Nurses assisting with monitoring the disease must report abnormal findings to the clinician. Only through a coordinated interprofessional approach to the care of the patient and education of the family will the best outcomes be achieved. [Level 5]



Hughes IA,Houk C,Ahmed SF,Lee PA, Consensus statement on management of intersex disorders. Archives of disease in childhood. 2006 Jul;     [PubMed PMID: 16624884]

Level 3 (low-level) evidence


Quigley CA,De Bellis A,Marschke KB,el-Awady MK,Wilson EM,French FS, Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine reviews. 1995 Jun;     [PubMed PMID: 7671849]

Level 3 (low-level) evidence


Berglund A,Johannsen TH,Stochholm K,Viuff MH,Fedder J,Main KM,Gravholt CH, Incidence, Prevalence, Diagnostic Delay, and Clinical Presentation of Female 46,XY Disorders of Sex Development. The Journal of clinical endocrinology and metabolism. 2016 Dec;     [PubMed PMID: 27603905]


Boehmer AL,Brinkmann O,Brüggenwirth H,van Assendelft C,Otten BJ,Verleun-Mooijman MC,Niermeijer MF,Brunner HG,Rouwé CW,Waelkens JJ,Oostdijk W,Kleijer WJ,van der Kwast TH,de Vroede MA,Drop SL, Genotype versus phenotype in families with androgen insensitivity syndrome. The Journal of clinical endocrinology and metabolism. 2001 Sep;     [PubMed PMID: 11549642]


Werner R,Holterhus PM, Androgen action. Endocrine development. 2014;     [PubMed PMID: 25247642]

Level 3 (low-level) evidence


Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet (London, England). 2012 Oct 20:380(9851):1419-28. doi: 10.1016/S0140-6736(12)60071-3. Epub 2012 Jun 13     [PubMed PMID: 22698698]


Bouvattier C,Carel JC,Lecointre C,David A,Sultan C,Bertrand AM,Morel Y,Chaussain JL, Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. The Journal of clinical endocrinology and metabolism. 2002 Jan;     [PubMed PMID: 11788616]


Hellmann P,Christiansen P,Johannsen TH,Main KM,Duno M,Juul A, Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Archives of disease in childhood. 2012 May;     [PubMed PMID: 22412043]

Level 2 (mid-level) evidence


Savage MO,Chaussain JL,Evain D,Roger M,Canlorbe P,Job JC, Endocrine studies in male pseudohermaphroditism in childhood and adolescence. Clinical endocrinology. 1978 Mar;     [PubMed PMID: 147759]


Hughes IA,Werner R,Bunch T,Hiort O, Androgen insensitivity syndrome. Seminars in reproductive medicine. 2012 Oct;     [PubMed PMID: 23044881]

Level 3 (low-level) evidence


Deeb A,Hughes IA, Inguinal hernia in female infants: a cue to check the sex chromosomes? BJU international. 2005 Aug;     [PubMed PMID: 16042738]


Hannema SE,Scott IS,Rajpert-De Meyts E,Skakkebaek NE,Coleman N,Hughes IA, Testicular development in the complete androgen insensitivity syndrome. The Journal of pathology. 2006 Mar;     [PubMed PMID: 16400621]


Poujol N,Lobaccaro JM,Chiche L,Lumbroso S,Sultan C, Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer. Molecular and cellular endocrinology. 1997 Jun 20;     [PubMed PMID: 9220020]

Level 3 (low-level) evidence


Griffin JE,Edwards C,Madden JD,Harrod MJ,Wilson JD, Congenital absence of the vagina. The Mayer-Rokitansky-Kuster-Hauser syndrome. Annals of internal medicine. 1976 Aug;     [PubMed PMID: 782313]

Level 3 (low-level) evidence


Levin HS, Tumors of the testis in intersex syndromes. The Urologic clinics of North America. 2000 Aug;     [PubMed PMID: 10985153]


Rajpert-de Meyts E,Hoei-Hansen CE, From gonocytes to testicular cancer: the role of impaired gonadal development. Annals of the New York Academy of Sciences. 2007 Dec;     [PubMed PMID: 18184914]

Level 3 (low-level) evidence


Cools M,Drop SL,Wolffenbuttel KP,Oosterhuis JW,Looijenga LH, Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocrine reviews. 2006 Aug;     [PubMed PMID: 16735607]

Level 2 (mid-level) evidence


Deans R,Creighton SM,Liao LM,Conway GS, Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clinical endocrinology. 2012 Jun;     [PubMed PMID: 22211628]

Level 3 (low-level) evidence


Amies Oelschlager AM, Debiec K. Vaginal Dilator Therapy: A Guide for Providers for Assessing Readiness and Supporting Patients Through the Process Successfully. Journal of pediatric and adolescent gynecology. 2019 Aug:32(4):354-358. doi: 10.1016/j.jpag.2019.05.002. Epub 2019 May 12     [PubMed PMID: 31091469]


Lucas-Herald A,Bertelloni S,Juul A,Bryce J,Jiang J,Rodie M,Sinnott R,Boroujerdi M,Lindhardt Johansen M,Hiort O,Holterhus PM,Cools M,Guaragna-Filho G,Guerra-Junior G,Weintrob N,Hannema S,Drop S,Guran T,Darendeliler F,Nordenstrom A,Hughes IA,Acerini C,Tadokoro-Cuccaro R,Ahmed SF, The Long-Term Outcome of Boys With Partial Androgen Insensitivity Syndrome and a Mutation in the Androgen Receptor Gene. The Journal of clinical endocrinology and metabolism. 2016 Nov     [PubMed PMID: 27403927]


Bouvattier C,Mignot B,Lefèvre H,Morel Y,Bougnères P, Impaired sexual activity in male adults with partial androgen insensitivity. The Journal of clinical endocrinology and metabolism. 2006 Sep;     [PubMed PMID: 16757528]


Pasterski V,Prentice P,Hughes IA, Consequences of the Chicago consensus on disorders of sex development (DSD): current practices in Europe. Archives of disease in childhood. 2010 Aug;     [PubMed PMID: 19773218]

Level 3 (low-level) evidence


Brain CE,Creighton SM,Mushtaq I,Carmichael PA,Barnicoat A,Honour JW,Larcher V,Achermann JC, Holistic management of DSD. Best practice     [PubMed PMID: 20541156]